Tempus AI Inc Q4 2024 Earnings Report
Key Takeaways
Tempus AI Inc saw a 35.8% year-over-year revenue growth in Q4 2024, reaching $200.7 million. The company reported a net loss of $13.0 million, significantly improving from the prior year's loss. Adjusted EBITDA also improved, and gross profit increased by 49.7%, driven by the growth in Data and Services. The company also announced its acquisition of Ambry Genetics, which is expected to strengthen its market position.
Q4 2024 revenue increased 35.8% YoY to $200.7 million.
Genomics revenue reached $120.4 million, while Data and Services generated $80.2 million.
Net loss improved to $13.0 million, compared to $50.5 million in Q4 2023.
Adjusted EBITDA improved to -$7.8 million from -$35.1 million in Q4 2023.
Tempus AI Inc Revenue
Tempus AI Inc EPS
Tempus AI Inc Revenue by Segment
Forward Guidance
Tempus AI expects FY 2025 revenue to reach $1.24 billion, with positive Adjusted EBITDA of $5 million.
Positive Outlook
- Projected 79% revenue growth in FY 2025.
- Expected positive Adjusted EBITDA of $5 million.
- Strong market positioning with the acquisition of Ambry Genetics.
- Expansion of AI-based diagnostic solutions.
- New reimbursement approvals for Tempus ECG-AF algorithm.
Challenges Ahead
- Ongoing net losses despite revenue growth.
- Stock-based compensation continues to impact profitability.
- Macroeconomic uncertainties may affect demand.
- Regulatory risks in AI-based healthcare solutions.
- Increased competition in the precision medicine industry.
Revenue & Expenses
Visualization of income flow from segment revenue to net income